Skip to main content
Erschienen in: Breast Cancer Research 4/2000

01.08.2000 | Review

Metalloproteinases: role in breast carcinogenesis, invasion and metastasis

Erschienen in: Breast Cancer Research | Ausgabe 4/2000

Einloggen, um Zugang zu erhalten

Abstract

The matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases. Their primary function is degradation of proteins in the extracellular matrix. Currently, at least 19 members of this family are known to exist. Based on substrate specificity and domain organization, the MMPs can be loosely divided into four main groups: the interstitial collagenases, gelatinases, stromelysins and membrane-type MMPs. Recent data from model systems suggest that MMPs are involved in breast cancer initiation, invasion and metastasis. Consistent with their role in breast cancer progression, high levels of at least two MMPs (MMP-2 and stromelysin-3) have been found to correlate with poor prognosis in patients with breast cancer. Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours
Literatur
1.
Zurück zum Zitat Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260. This is a comprehensive overview on the multiple roles of MMPs in cancer initiation and progression.CrossRefPubMed Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260. This is a comprehensive overview on the multiple roles of MMPs in cancer initiation and progression.CrossRefPubMed
2.
Zurück zum Zitat Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol. 1998, 12: 1343-1348. This paper examines the prognostic and therapeutic potential of MMPs in cancer.PubMed Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol. 1998, 12: 1343-1348. This paper examines the prognostic and therapeutic potential of MMPs in cancer.PubMed
3.
Zurück zum Zitat Balbin M, Pendas AM, Uria JA, et al: Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS. 1999, 107: 45-53.CrossRefPubMed Balbin M, Pendas AM, Uria JA, et al: Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS. 1999, 107: 45-53.CrossRefPubMed
4.
Zurück zum Zitat Levi E, Fridman R, Miao H-Q, et al: Matrix metalloproteinase releases active soluble ectodomain of fibroblast growth factor 1. Proc Natl Acad Sci USA. 1996, 93: 7069-7074. 10.1073/pnas.93.14.7069.CrossRefPubMedPubMedCentral Levi E, Fridman R, Miao H-Q, et al: Matrix metalloproteinase releases active soluble ectodomain of fibroblast growth factor 1. Proc Natl Acad Sci USA. 1996, 93: 7069-7074. 10.1073/pnas.93.14.7069.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Rei D, Majmudar G, Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem . 1994, 269: 25849-25855. Rei D, Majmudar G, Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem . 1994, 269: 25849-25855.
6.
Zurück zum Zitat Murphy G, Segain JP, O'Shea M, et al: The 28 kD N-terminal domain of mouse stromelysin-3 has the general properties of a weak stromelysin-like metalloproteinase. J Biol Chem. 1993, 268: 15435-15441.PubMed Murphy G, Segain JP, O'Shea M, et al: The 28 kD N-terminal domain of mouse stromelysin-3 has the general properties of a weak stromelysin-like metalloproteinase. J Biol Chem. 1993, 268: 15435-15441.PubMed
7.
Zurück zum Zitat Pei D, Weiss S: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995, 375: 244-247. 10.1038/375244a0.CrossRefPubMed Pei D, Weiss S: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995, 375: 244-247. 10.1038/375244a0.CrossRefPubMed
8.
Zurück zum Zitat Seki M: Membrane-type matrix metalloproteinases. Review article. APMIS. 1999, 107: 137-143.CrossRef Seki M: Membrane-type matrix metalloproteinases. Review article. APMIS. 1999, 107: 137-143.CrossRef
9.
Zurück zum Zitat Ohuchi E, Imai K, Fujii Y, et al: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997, 272: 2446-2451. 10.1074/jbc.272.4.2446.CrossRefPubMed Ohuchi E, Imai K, Fujii Y, et al: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997, 272: 2446-2451. 10.1074/jbc.272.4.2446.CrossRefPubMed
10.
Zurück zum Zitat Hiraoka N, Allen E, Apel IJ, et al: Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998, 95: 365-377.CrossRefPubMed Hiraoka N, Allen E, Apel IJ, et al: Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998, 95: 365-377.CrossRefPubMed
11.
Zurück zum Zitat Stone AL, Kroeger M, Amy Sang QX: Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins [review]. J Prot Chem. 1999, 18: 447-465. 10.1023/A:1020692710029. A comprehensive and up-to-date review on ADAMs is provided.CrossRef Stone AL, Kroeger M, Amy Sang QX: Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins [review]. J Prot Chem. 1999, 18: 447-465. 10.1023/A:1020692710029. A comprehensive and up-to-date review on ADAMs is provided.CrossRef
12.
Zurück zum Zitat Henriet P, Blavier L, DeClerck YA: Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS. 1999, 107: 111-119. This paper reviews the role of TIMPs in cancer proliferation and invasion.CrossRefPubMed Henriet P, Blavier L, DeClerck YA: Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS. 1999, 107: 111-119. This paper reviews the role of TIMPs in cancer proliferation and invasion.CrossRefPubMed
13.
Zurück zum Zitat Amour A, Slocombe PM, Webster A, et al: TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett . 1998, 435: 39-41. 10.1016/S0014-5793(98)01031-X.CrossRefPubMed Amour A, Slocombe PM, Webster A, et al: TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett . 1998, 435: 39-41. 10.1016/S0014-5793(98)01031-X.CrossRefPubMed
14.
Zurück zum Zitat Guedez L, Stetler-Stevenson WG, Wolf L, et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinase-1. J Clin Invest. 1998, 102: 2002-2010.CrossRefPubMedPubMedCentral Guedez L, Stetler-Stevenson WG, Wolf L, et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinase-1. J Clin Invest. 1998, 102: 2002-2010.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Valente P, Fassina G, Melchiori A, et al: TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998, 75: 246-253. 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B.CrossRefPubMed Valente P, Fassina G, Melchiori A, et al: TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998, 75: 246-253. 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B.CrossRefPubMed
16.
Zurück zum Zitat Baker AH, George SJ, Zaltsman AB, et al: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999, 79: 1347-1355. 10.1038/sj.bjc.6690217.CrossRefPubMedPubMedCentral Baker AH, George SJ, Zaltsman AB, et al: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999, 79: 1347-1355. 10.1038/sj.bjc.6690217.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Benz CC: Transcriptional factors and breast cancer. Endoc Rel Cancers. 1998, 5: 271-282. This paper examines the involvement of transcriptional factors in breast carcinogenesis.CrossRef Benz CC: Transcriptional factors and breast cancer. Endoc Rel Cancers. 1998, 5: 271-282. This paper examines the involvement of transcriptional factors in breast carcinogenesis.CrossRef
18.
Zurück zum Zitat Giunciuglio D, Culty M, Fassina G, et al: Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer. 1995, 63: 815-822.CrossRefPubMed Giunciuglio D, Culty M, Fassina G, et al: Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer. 1995, 63: 815-822.CrossRefPubMed
19.
Zurück zum Zitat Kaya M, Yoshida K, Higashino F, et al: A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene. 1996, 12: 221-227.PubMed Kaya M, Yoshida K, Higashino F, et al: A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene. 1996, 12: 221-227.PubMed
20.
Zurück zum Zitat Wiesen JF, Werb Z: The role of stromelysin-1 in stromal-epithelial interactions and cancer. Enzyme Protein. 1996, 49: 174-181.PubMed Wiesen JF, Werb Z: The role of stromelysin-1 in stromal-epithelial interactions and cancer. Enzyme Protein. 1996, 49: 174-181.PubMed
21.
22.
Zurück zum Zitat Rio M-C, Lefebvre O, Santavicca M, et al: Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J Mam Gland Neoplasia. 1996, 1: 231-240.CrossRef Rio M-C, Lefebvre O, Santavicca M, et al: Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J Mam Gland Neoplasia. 1996, 1: 231-240.CrossRef
23.
Zurück zum Zitat Masson R, Lefebvre R, Noel A, et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 1998, 140: 1535-1541. 10.1083/jcb.140.6.1535.CrossRefPubMedPubMedCentral Masson R, Lefebvre R, Noel A, et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 1998, 140: 1535-1541. 10.1083/jcb.140.6.1535.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Rudolph-Owen LA, Chan R, Muller WJ, et al: The matrix metalloproteinase matrilysin influences early stage mammary tumorigenesis. Cancer Res. 1988, 58: 5500-5506. Rudolph-Owen LA, Chan R, Muller WJ, et al: The matrix metalloproteinase matrilysin influences early stage mammary tumorigenesis. Cancer Res. 1988, 58: 5500-5506.
25.
Zurück zum Zitat Sledge GWJ, Qulali M, Goulet R, et al: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst. 1995, 87: 1546-1550.CrossRefPubMed Sledge GWJ, Qulali M, Goulet R, et al: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst. 1995, 87: 1546-1550.CrossRefPubMed
26.
Zurück zum Zitat Wang M, Liu YE, Greene J, et al: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase. Oncogene. 1997, 14: 2767-2774. 10.1038/sj.onc.1201245.CrossRefPubMed Wang M, Liu YE, Greene J, et al: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase. Oncogene. 1997, 14: 2767-2774. 10.1038/sj.onc.1201245.CrossRefPubMed
27.
Zurück zum Zitat Zetter B: Angiogenesis and tumor metastasis. Annu Rev Med. 1998, 49: 407-424. 10.1146/annurev.med.49.1.407. This is an comprehensive and up-to-date review on the role of angiogenesis in tumour metastasis.CrossRefPubMed Zetter B: Angiogenesis and tumor metastasis. Annu Rev Med. 1998, 49: 407-424. 10.1146/annurev.med.49.1.407. This is an comprehensive and up-to-date review on the role of angiogenesis in tumour metastasis.CrossRefPubMed
28.
Zurück zum Zitat Stetler-Stevenenson W: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999, 103: 1237-1241. A review of the role of MMPs in angiogenesis is presented.CrossRef Stetler-Stevenenson W: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999, 103: 1237-1241. A review of the role of MMPs in angiogenesis is presented.CrossRef
29.
Zurück zum Zitat Peschon JJ, Slack JL, Reddy P, et al: An essential role for ectodomain shedding in mammalian development. Science. 1998, 282: 1281-1284. 10.1126/science.282.5392.1281.CrossRefPubMed Peschon JJ, Slack JL, Reddy P, et al: An essential role for ectodomain shedding in mammalian development. Science. 1998, 282: 1281-1284. 10.1126/science.282.5392.1281.CrossRefPubMed
30.
Zurück zum Zitat Dong J, Opresko LK, Dempsey PJ, et al: Metalloprotease-mediated ligand release regulates autocrine signalling through the epidermal growth factor receptor. Proc Natl Acad Sci USA. 1999, 96: 6235-6240. 10.1073/pnas.96.11.6235. This is a comprehensive review of the main steps and molecules involved in metastasis.CrossRefPubMedPubMedCentral Dong J, Opresko LK, Dempsey PJ, et al: Metalloprotease-mediated ligand release regulates autocrine signalling through the epidermal growth factor receptor. Proc Natl Acad Sci USA. 1999, 96: 6235-6240. 10.1073/pnas.96.11.6235. This is a comprehensive review of the main steps and molecules involved in metastasis.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Codony-Servat J, Albanell J, Lopez-Talavera JC, et al: Clevage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue-inhibitor of metalloprotease-1 in breast cancer cells. Cancer Res. 1999, 59: 1196-1201.PubMed Codony-Servat J, Albanell J, Lopez-Talavera JC, et al: Clevage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue-inhibitor of metalloprotease-1 in breast cancer cells. Cancer Res. 1999, 59: 1196-1201.PubMed
32.
Zurück zum Zitat Eccles SA, Box GM, Court WJ, et al: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimistat (BB-94). Cancer Res . 1996, 56: 2815-2822.PubMed Eccles SA, Box GM, Court WJ, et al: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimistat (BB-94). Cancer Res . 1996, 56: 2815-2822.PubMed
33.
Zurück zum Zitat Lochter A, Srebrow A, Sympson CJ, et al: Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1 dependent invasive properties. J Biol Chem. 1997, 272: 5007-5015. 10.1074/jbc.272.8.5007.CrossRefPubMed Lochter A, Srebrow A, Sympson CJ, et al: Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1 dependent invasive properties. J Biol Chem. 1997, 272: 5007-5015. 10.1074/jbc.272.8.5007.CrossRefPubMed
34.
Zurück zum Zitat Davies B, Miles DW, Happerfield MLC, et al: Activity of type IV collagenase in benign and malignant breast tissue. Br J Cancer. 1993, 67: 1126-1131.CrossRefPubMedPubMedCentral Davies B, Miles DW, Happerfield MLC, et al: Activity of type IV collagenase in benign and malignant breast tissue. Br J Cancer. 1993, 67: 1126-1131.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bis-phosphonate ibandronate and tissue inhibitor of the matrix metal-loproteinase-2. J Clin Invest. 1997, 99: 2509-2517.CrossRefPubMedPubMedCentral Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bis-phosphonate ibandronate and tissue inhibitor of the matrix metal-loproteinase-2. J Clin Invest. 1997, 99: 2509-2517.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Barsky S, Togo S, Garbisa S, et al: Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet. 1983, i: 296-297.CrossRef Barsky S, Togo S, Garbisa S, et al: Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet. 1983, i: 296-297.CrossRef
37.
Zurück zum Zitat Lochter A, Bissell MJ: An odyssey from breast to bone: multistep control of mammary metastases and osteolysis by matrix matalloproteinases. APMIS. 1999, 107: 128-136.CrossRefPubMedPubMedCentral Lochter A, Bissell MJ: An odyssey from breast to bone: multistep control of mammary metastases and osteolysis by matrix matalloproteinases. APMIS. 1999, 107: 128-136.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Duffy MJ: The biochemistry of metastasis. Adv Clin Chem . 1996, 32: 136-166. Duffy MJ: The biochemistry of metastasis. Adv Clin Chem . 1996, 32: 136-166.
39.
Zurück zum Zitat Duffy MJ: Do proteases play a role in cancer invasion and metastasis?. Eur J Cancer Clin Oncol. 1987, 23: 583-589.CrossRefPubMed Duffy MJ: Do proteases play a role in cancer invasion and metastasis?. Eur J Cancer Clin Oncol. 1987, 23: 583-589.CrossRefPubMed
40.
Zurück zum Zitat Talvensaari-Mattila A, Paakko P, Hoyhtya M, et al: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998, 83: 1153-1162. 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.3.CO;2-0.CrossRefPubMed Talvensaari-Mattila A, Paakko P, Hoyhtya M, et al: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 1998, 83: 1153-1162. 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.3.CO;2-0.CrossRefPubMed
41.
Zurück zum Zitat McCarthy K, Maguire T, McGreal G, et al: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999, 84: 44-48. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G.CrossRefPubMed McCarthy K, Maguire T, McGreal G, et al: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999, 84: 44-48. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G.CrossRefPubMed
42.
Zurück zum Zitat Remackle A, McCarthy K, Noel A, et al: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer. 2000, 89: 118-121. 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8.CrossRef Remackle A, McCarthy K, Noel A, et al: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer. 2000, 89: 118-121. 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8.CrossRef
43.
Zurück zum Zitat Andreasen P, Kjoller L, Christensen L, et al: The urokinase-type plasminogen activator in cancer metastasis: a review. Int J Cancer. 1997, 72: 1-22. 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z.CrossRefPubMed Andreasen P, Kjoller L, Christensen L, et al: The urokinase-type plasminogen activator in cancer metastasis: a review. Int J Cancer. 1997, 72: 1-22. 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z.CrossRefPubMed
44.
Zurück zum Zitat Talbot DC, Brown P: Experimental and clinical studies on the use of matrix metalloproteinases inhibitors for the treatment of cancer. Eur J Cancer. 1996, 32A: 2528-2533. 10.1016/S0959-8049(96)00398-X.CrossRefPubMed Talbot DC, Brown P: Experimental and clinical studies on the use of matrix metalloproteinases inhibitors for the treatment of cancer. Eur J Cancer. 1996, 32A: 2528-2533. 10.1016/S0959-8049(96)00398-X.CrossRefPubMed
45.
Zurück zum Zitat Brown P: Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999, 107: 174-180.CrossRefPubMed Brown P: Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999, 107: 174-180.CrossRefPubMed
46.
Zurück zum Zitat Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer. Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998, 4: 1101-1109.PubMed Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer. Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998, 4: 1101-1109.PubMed
47.
Zurück zum Zitat Dano K, Romer J, Nielsen BS, et al: Cancer invasion and tissue remodelling: cooperation of protease systems and cell types. APMIS. 1999, 107: 120-127.CrossRefPubMed Dano K, Romer J, Nielsen BS, et al: Cancer invasion and tissue remodelling: cooperation of protease systems and cell types. APMIS. 1999, 107: 120-127.CrossRefPubMed
48.
Zurück zum Zitat Mitsiades N, Poulaki V, Leone A, et al: Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst. 1999, 91: 1678-1684. 10.1093/jnci/91.19.1678.CrossRefPubMed Mitsiades N, Poulaki V, Leone A, et al: Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst. 1999, 91: 1678-1684. 10.1093/jnci/91.19.1678.CrossRefPubMed
Metadaten
Titel
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
Publikationsdatum
01.08.2000
Erschienen in
Breast Cancer Research / Ausgabe 4/2000
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr65

Weitere Artikel der Ausgabe 4/2000

Breast Cancer Research 4/2000 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.